ArticleAmerican journal of translational research2026
Kangfuxin liquid enema plus adalimumab for ulcerative colitis: a retrospective cohort study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUlcerative colitis (UC) is a chronic inflammatory bowel disease requiring effective treatment. This study aimed to evaluate the efficacy and safety of Kangfuxin liquid enema combined with adalimumab compared to adalimumab monotherapy in patients with UC.
methodsThis retrospective cohort study included 240 UC patients treated between June 2022 and January 2024. Patients were divided into a combination therapy group (CT, adalimumab + Kangfuxin enema, n = 123) and a monotherapy group (MT, adalimumab alone, n = 117). We assessed clinical efficacy, adverse reactions, quality of life, serum inflammatory cytokines (interleukin-1 beta [IL-1β], interleukin-8 [IL-8], tumor necrosis factor-alpha [TNF-α]), endoscopic scores (Mayo, Baron), histologic score (Geboes), oxidative stress indicators (superoxide dismutase [SOD], malondialdehyde [MDA]), and intestinal barrier indicators (diamine oxidase [DAO], D-lactate) before and after 8 weeks of treatment.
resultsOverall response rate observed in the CT cohort (88.62%) significantly exceeded that of the MT cohort (73.50%, P = 0.003). Mucosal healing rates were 56.10% vs. 32.48% (P < 0.001). Endoscopic remission rates were 65.04% vs. 47.01% (P = 0.005). Post-treatment inflammatory factor levels were decreased in the CT group (all P < 0.001). Oxidative stress and intestinal barrier markers also improved more in the CT group (all P < 0.001). Moreover, patient-reported quality of life (assessed by IBDQ-32) improved significantly more in the CT group (P < 0.001). Adverse reaction incidence (8.94% vs. 23.94%, P = 0.002) was decreased in the CT group.
conclusionCombining Kangfuxin liquid enema and adalimumab was more effective and safer than adalimumab alone in the treatment of ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.